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Here we demonstrate that reprogramming steroid receptor coac-
tivator-3 (SRC-3) function by changing its posttranslational modi-
ﬁcation (PTM) code drastically inﬂuences systems biology. These
ﬁndings support the physiological importance of PTMs in directing
in vivo functions of a master coregulator. We previously reported
that the transactivation potential of SRC-3 is controlled in part by
PTMs, although this data emanated from in vitro studies. To test
the physiological implications of PTMs on SRC-3, we developed
a knock-in mouse model containing mutations at four conserved
phosphorylation sites. Thesemice displayed a systems biology phe-
notype with increased body weight and adiposity, coupled with
reduced peripheral insulin sensitivity. Collectively, these pheno-
types result from increased IGF1 signaling, due to elevated IGFBP3
levels. We provide convincing evidence that these mutations in
SRC-3 promoted enhanced transcription of the IGFBP3 gene and
globally inﬂuenced growth and metabolism. Consequently, these
mice displayed increased liver tumorigenesis, which likely results
from elevated IGF1 signaling.
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Gene expression is a highly coordinated process that requiresa delicate crosstalk between the basal transcriptional ma-
chinery, transcription factors, and transcriptional coregulators.
Built into each of these components is an evolutionarily tuned
code of posttranslational modiﬁcations (PTMs) that regulate the
activity, association/dissociation, localization, and turnover of
many proteins. This regulation is especially true for the p160
family of coactivators, whose global function, enzymatic activity,
and stability are tightly controlled by PTMs (1–4).
The p160 family of coactivators, which include steroid receptor
coactivator (SRC)-1, SRC-2, and SRC-3 (AIB1, p/CIP, NCoA3)
have pleiotropic effects in different physiological systems (5).
Central to these physiological functions are the unique roles these
coactivators play in maintenance of metabolic homeostasis. Al-
though these three coactivators are critical for preserving normal
metabolic function, each coactivator has a selective role in energy
homeostasis. For example, SRC-1 plays a key role in regulation of
energy expenditure, and its deletion confers susceptibility to diet-
induced obesity (6). Additionally, SRC-1 seems to be an important
regulator of hepatic gluconeogenesis and coordinates regulation of
protein metabolism. By contrast, deletion of SRC-2 provides pro-
tection against diet-induced obesity through enhanced energy ex-
penditure (6). Moreover, we have shown that SRC-2 is important
for hepatic glucose output (7). Lastly, ablation of SRC-3, which is
essential for maintenance of white adipose tissue differentiation,
protects against obesity and improves insulin sensitivity (8, 9).
Collectively, these ﬁndings establish the p160 family of coactivators
as important regulators of metabolic homeostasis.
In line with its metabolic functions, SRC-3 has been shown
to dynamically regulate cell proliferation (10). Ampliﬁcation of
SRC-3 has been reported in numerous cancers such as breast,
prostate, lung, colorectal, pancreatic, and liver (5). Mechanisti-
cally, SRC-3 exerts its inﬂuence on cell growth by serving as
an integrator of multiple proliferative pathways. SRC-3 interacts
with, and stimulates the transcriptional output of powerful
oncogenes such as E2F1, HER2/neu, C/EPBβ, and NFκB, each of
which regulates distinct components of the proliferative machin-
ery (8, 11–13). In addition to these growth regulators, SRC-3
expression and activity are closely and positively associated with
the IGF1 signaling pathway. Loss of the SRC-3 gene confers
a reduction in circulating IGF1, primarily due to a decrease of
IGFBP3 levels (14). Consequently, multiple downstream path-
ways of AKT signaling are affected, leading to a deﬁciency in
growth-related targets such as cyclin D1 and β-catenin (15, 16).
Much of SRC-3 function in proliferation is thought to be facili-
tated through changes in the posttranslational code of the pro-
tein. We have found that the SRC-3 coactivator contains >50
authentic PTMs of various types. Work in cultured cells from our
laboratory clearly established that site-speciﬁc phosphorylation
events not only impact SRC-3′s transcriptional activity and tran-
scription factor selectivity, but also facilitate turnover of activa-
ted SRC-3 upon completion of transcription (3). Numerous in
vitro and in vivo studies have established SRC-3 as a key regulator
of systems biology (17). Moreover, cell-based and cell-free sys-
tems have clearly demonstrated a mechanistic role for PTMs in
controlling SRC-3 function and activity. In the present study, we
developed a knock-in mouse model containing mutations in four
conserved phosphorylation sites in SRC-3. Interestingly, the ef-
fects of these mutations result in phenotypes opposite to the
SRC-3−/− mouse model, including increased body weight and
adiposity, decreased metabolic rate, and the development of in-
sulin resistance. Collectively, our results provide evidence that
changes in the functional PTM code of a nuclear receptor coac-
tivator (SRC-3) confer systemic changes in growth and metabo-
lism in the absence of an alteration in the normal levels of
the protein.
Results
Generation of SRC-3Δ/Δ Knock-in Mice. To evaluate the in vivo
function of PTMs in SRC-3, we generated a knock-in mouse
model harboring alanine mutations in four phosphorylation sites
conserved in human and mouse SRC-3 (Fig. 1A, Fig. S1A, and
Table S1). As conﬁrmed by Southern blot, the targeted homolo-
gous recombination in ES cells resulted in the successful insertion
of the mutations and the selection marker (Fig. S1B). Positively
identiﬁed clones validated by DNA sequencing to conﬁrm the
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point mutations and proper insertion of the selection cassette
were used to develop chimeric mice, which were crossed to wild-
type (WT) females to produce heterozygous mice (SRC-3Δ/+).
The resulting heterozygotes were bred to generate SRC-3 ho-
mozygous knock-in mice (SRC-3Δ/Δ) (Fig. S1C). To further con-
ﬁrm the presence of the engineered point mutants, RPA probes
were generated to discriminate between the WT and mutant
sequences (Fig. S1D). Point mutations in the SRC-3Δ/Δ mouse
remain under the control of the endogenous promoter. qPCR
revealed no changes in mRNA levels of SRC-3, or the other two
SRC family members in different tissues (Fig. S1 E–G).
Our previous in vitro data demonstrated that mutation of cer-
tain conserved phosphorylation sites might be sufﬁcient to alter
the protein levels of SRC-3 (3). To evaluate the collective effect of
the four knock-in point mutations on SRC-3 protein stability,
Western blot analysis was performed on mouse embryonic ﬁbro-
blasts (MEFs) isolated from WT and SRC-3Δ/Δ mice (Fig. 1B).
These results suggest that the knock-in mutations have no sig-
niﬁcant effect on SRC-3 protein expression. Moreover, MEF cells
were treated with cycloheximide for stability analyses showed
a slight increase in the half-life of SRC-3 (Fig. S1H). Additionally,
Western blot analysis of liver tissue isolated from knock-in and
WTmice revealed no substantial differences in the in vivo protein
expression of SRC-3 (Fig. 1C).
SRC-3Δ/Δ Mice Display Increased Body Weight and Composition. Ini-
tial observations of the SRC-3Δ/Δmice revealed an increase in body
weight starting just before weaning and continuing throughout life.
This phenotype is opposite of what was observed in growth of
SRC-3−/− mice (18). Body weight of the SRC-3Δ/Δ mice was ini-
tially ≈10% greater than WT, but this difference continued and
became greater with age (Fig. 1D). At 1 y of age, SRC-3Δ/Δ mice
were ≈15% larger than WT mice (Fig. 1E), suggesting a global
growth enhancement. Body composition analysis revealed that
SRC-3Δ/Δ mice have a comprehensive increase in whole body ar-
chitecture (Fig. 1F). Interestingly, SRC-3Δ/Δ mice had more fat
mass but no statistical difference in lean body mass, indicative of
increased adiposity.
SRC-3Δ/Δ Mice Show Global Metabolic Defects. To better understand
the cause of the increased body weight and composition in the
SRC-3Δ/Δ mice, we evaluated a number of metabolic parameters.
Resting energy expenditure and heat production, as measured by
indirect calorimetry, revealed no differences between SRC-3Δ/Δ
andWTmice (Fig. S2 and Fig. 2A). Upon exercise-induced stress,
SRC-3Δ/Δ mice showed a minimal reduction in energy expendi-
ture, but this difference is unlikely to explain the changes in body
weight (Fig. 2B). Based on the persistent increase in body weight,
we evaluated food intake as an assessment of metabolic homeo-
stasis and, surprisingly, found that SRC-3Δ/Δ mice had a minor
reduction in food consumption (Fig. 2C). Further evaluation of
energy absorption, as measured by monitoring mice in metabolic
cages, revealed that SRC-3Δ/Δ mice had reduced waste disposal
(Fig. S3 A–C), most likely resulting from a decrease in food in-
take, but increased absorption cannot be completely excluded.
Body composition and metabolic activity have been well es-
tablished to inﬂuence physical activity (19). Metabolic monitoring
of locomotor activity revealed a substantial decrease in activity in
SRC-3Δ/Δmice (Fig. 2D–G).Additionally, SRC-3Δ/Δmice showed
a signiﬁcant reduction in resting body temperature, another index
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Fig. 1. Development and characterization of the SRC-3Δ/Δmice. (A) Targeting construct designed to insert serine to alaninemutations into the SRC-3 gene locus.
(B) Western blot of SRC-3 and α-tubulin fromprimaryMEFs isolated fromWTand SRC-3Δ/Δmice. (C)Western blots of SRC-3 and β-actin in liver tissue isolated from
WT (n = 4) and SRC-3Δ/Δ mice (n = 4). (D) Increased body weights in SRC-3Δ/Δ mice compared with WT littermates as observed from 4 to 52 wk. (E) Photograph
depicts the appearance of 9-mo-old SRC-3Δ/Δ andWT littermate male mice. (F) DEXA body composition analysis of SRC-3Δ/Δmice (ﬁlled bars; n = 5) andWTmice
(open bars; n = 5). All data are represented as the mean ± SEM. Unpaired Student’s t test was used to evaluate statistical signiﬁcance. *, P < 0.05; **, P < 0.01.
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of basal metabolic homeostasis (Fig. 2H). SRC-3Δ/Δmice appear to
be protected slightly from decreased body temperature in response
to fasting (Fig. 2H). A more deﬁnitive analysis of adaptive ther-
mogenesis clearly revealed that although SRC-3Δ/Δ mice initially
showed a slightly reduced body temperature, these mice are able to
maintain body temperature in response to cold (Fig. 2I).
SRC-3Δ/Δ Mice Exhibit Elevated IGF1 Signaling. Whole-body com-
position analysis of the SRC-3Δ/Δ mice suggested an increase in
a global growth-controlling pathway. A previous study from our
laboratory revealed that ablation of SRC-3 reduces IGF1 by de-
creasing SRC-3-mediated IGFBP3 gene transcription (14). Con-
versely, SRC-3Δ/Δmice showed a marked increase in total plasma
IGF1 (Fig. 3A). Analysis of IGF1 gene transcription in both liver
and kidney revealed that elevated circulating levels of IGF1 were
not likely due to increased synthesis of the hormone (Fig. S4B).
Evaluation of in vivo human IGF1 turnover revealed no signiﬁ-
cant differences in the SRC-3Δ/Δ mice (Fig. S4C); however, this
result could be partially inﬂuenced by elevated levels of mouse
IGF1 in the circulation. Analysis of plasma IGFBP3 by ELISA
Fig. 2. SRC-3Δ/Δ mice show global metabolic defects. (A) Heat generation of SRC-3Δ/Δ mice (ﬁlled bars, n = 6) and WT (open bars, n = 6) littermate mice. (B)
Exercise-induced calorimetry of SRC-3Δ/Δ (ﬁlled bars; n = 6) and WT mice (open bars; n = 6). (C) SRC-3Δ/Δ mice (ﬁlled bars; n = 6) have reduced food intake
compared with WT mice (open bars; n = 6). (D–G) Locomotor activity was measured in SRC-3Δ/Δ (ﬁlled bars; n = 6) and WT mice (open bars; n = 6). The average
horizontal movement, distance traveled, movement time, and number of movements during a 24-h monitoring period are shown. (H) Resting rectal body
temperature of SRC-3Δ/Δ mice (ﬁlled bars; n = 5) compared with WT littermate mice (open bars; n = 5) during fed or 24 h fasted conditions. (I) Adaptive
thermogenesis of SRC-3Δ/Δ mice (ﬁlled bars; n = 6) compared with WT littermate mice (open bars; n = 6) measured over a 6-h period. All data are represented
as the mean ± SEM. Unpaired Student’s t test was used to evaluate statistical signiﬁcance. *, P < 0.05; **, P < 0.01.
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Fig. 3. SRC-3Δ/Δ mice exhibit elevated IGF1 signaling. (A)
Plasma levels of total IGF1 in SRC-3Δ/Δ mice (ﬁlled bars; n = 5)
compared withWT littermate mice (open bars; n = 5). (B) ELISA
analysis of plasma IGFBP3 in SRC-3Δ/Δ mice (n = 5) compared
with WT littermate mice (n = 5). (C) Analysis of plasma IGF
binding proteins (IGFBP-2, -3, -4) in SRC-3Δ/Δ mice (n = 5) com-
pared with WT littermate mice (n = 5) measured by 125I-IGF1
binding. Densitometry of IGFBP3 in SRC-3Δ/Δ mice (ﬁlled bars)
compared with WT littermate mice (open bars) were normal-
ized to IGFBP4 levels. (D) Quantitative real-time PCR analysis of
IGFBP3 and IGFBP4. RNAs were isolated from kidney and livers
of SRC-3Δ/Δ (ﬁlledbars;n=5)andWTlittermatemice (openbars;
n = 5). Expression levels of each gene were normalized to the
levels of 18S rRNA. (E) SRC-3Δ/Δ mutations lead to increased
transcriptionalactivationof the IGFBP3promoter. PrimaryMEFs
from SRC-3Δ/Δ (ﬁlled bars) and WT littermate mice (open bars)
were transiently transfected with 3.6 Kb of the IGFBP3 WT
promoter-luciferase construct or empty vector. All data were
normalized to β-gal. (F) In vivo ChIP of SRC-3 from perfused
kidney from SRC-3Δ/Δ (n = 3) and WT littermate mice (n = 3).
Data are presented as fold SRC-3 signal over IgG. Amplicon is
directed toward a conserved VDRE at ≈3.5 Kb or at ≈1.2 Kb
upstreamofthe transcriptional start site, respectively. (G) In vivo
ChIP of SRC-3 from perfused kidney from SRC-3−/−mice (n = 4).
Amplicon is directed toward a conserved VDRE at ≈3.5 Kb or
at ≈1.2 Kb upstream of the transcriptional start site, respec-
tively. All data are presented as fold SRC-3 signal over IgG. All
data are represented as the mean ± SEM. Unpaired Student’s
t test was used to evaluate statistical signiﬁcance. *, P < 0.05.
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revealed a moderate increase in SRC-3Δ/Δ mice (Fig. 3B), con-
sistent with ligand blot analysis using 125I-IGF1 to measure levels
of IGF binding proteins in the circulation (Fig. 3C). Changes in
growth hormone are known to inﬂuence the levels of IGF1, but we
observed no changes in plasma growth hormone betweenWT and
SRC-3Δ/Δ mice (Fig. S4D). Likewise, we observed no changes in
plasma thyroid-stimulating hormone (TSH) between WT and
SRC-3Δ/Δ mice (Fig. S4E). Synthesis of new IGF1 binding pro-
teins primarily occurs in the kidney and, to a lesser extent, in the
liver (20). Kidney and liver expression levels of IGFBP3 and
IGFBP-4 mRNAs were highly consistent with IGFBP plasma
levels, where SRC-3Δ/Δ mice revealed a marked increase speciﬁ-
cally in IGFBP3 mRNA in both kidney and liver (Fig. 3D).
To substantiate that the effects on IGFBP3 gene transcription
were mediated by mutations in SRC-3, we performed luciferase
reporter assays by using a reporter construct consisting of ≈3,600
bp of the IGFBP3 proximal promoter. Consistent with the tissue
expression levels of IGFBP3, primary MEFs from SRC-3Δ/Δmice
efﬁciently promoted gene transcription on the IGFBP3 promoter
compared with WT MEFs (Fig. 3E). To determine whether the
increased IGFBP3 gene transcription in the presence of the
SRC-3mutant is gene-speciﬁc or represents a general mechanism,
we performed ERE luciferase reporter assays. Consistent with
IGFBP3 gene transcription, mutant SRC-3 more efﬁciently co-
activated ER-mediated gene transcription compared with WT
SRC-3 (Fig. S4A), suggesting that mutant SRC-3 confers a more
general increase in gene transcription. Importantly, in vivo ChIP
of SRC-3 from kidney tissue isolated from SRC-3Δ/Δ and WT
mice revealed no change in occupancy on the IGFBP3 promoter
(Fig. 3F). Speciﬁcity of SRC-3 occupancy on the IGFBP3 pro-
moter was conﬁrmed by in vivo ChIP from kidney isolated from
SRC-3−/− mice (Fig. 3G). Taken together, our data suggest that
the mutations in SRC-3 confer an increase in transcriptional
output of IGFBP3 independent of levels of promoter occupancy.
SRC-3Δ/Δ Mice Display the Hallmarks of Insulin Resistance. Previously
reported data clearly demonstrated that overexpression of IGFBP3
in mice results in hyperglycemia and leads to reduced insulin sen-
sitivity (21, 22). Consistent with those reports, SRC-3Δ/Δ mice de-
veloped hyperglycemia, which is observed during both ad libitum
and 24-h fasting conditions (Fig. 4A Left). SRC-3Δ/Δ mice also dis-
played an elevation in fasting insulin levels (Fig. 4A Right), along
with a decrease in fasting glucagon (Fig. S5A), implicating insulin
resistance. The hyperglycemia appears to be age-dependent, be-
cause at a younger age, SRC-3Δ/Δ mice showed a trend toward hy-
perglycemia, but these data failed to reach signiﬁcance (Fig. S5B).
Moreover, a glucose tolerance test revealed that SRC-3Δ/Δ mice
have abnormal glucose tolerance when compared with WT mice
(Fig. 4BLeft). In fact, even though SRC-3Δ/Δmice showed increased
circulating insulin levels in response to a glucose challenge, this
adaptive response was still incapable of normalizing blood glucose
(Fig. 4B Right). Further evaluation using an insulin tolerance test
revealed that SRC-3Δ/Δ mice are less effective at achieving nor-
moglycemia (Fig. 4C). Collectively, these data clearly point to the
development of insulin resistance in the SRC-3Δ/Δ mouse.
Consistent with reports of the IGFBP3 transgenic mice,
SRC-3Δ/Δ mice also showed increased glycogen content in liver
as determined by Periodic acid-Schiff staining (PAS) (Fig. 4D)
and enzymatic quantitation (Fig. 4E). In line with insulin re-
sistance, SRC-3Δ/Δ mice showed increased hepatic storage of
triglycerides (Fig. 4D) and elevated circulating triglycerides
(Fig. 4F). However, SRC-3Δ/Δ mice maintained normal circu-
lating levels of cholesterol and fatty acids (Fig. S6 A and B).
Also, mirroring the IGFBP3 transgenic mice, SRC-3Δ/Δ mice
showed increased adiposity. This observation correlates with
increased adipocyte size (Fig. 4D), as conﬁrmed by quantitation
of H&E sections of white adipose tissue (Fig. S6C), and an in-
crease in the adipose-secreted hormone leptin (Fig. S6D),
whereas the level of adiponectin was substantially reduced (Fig.
4G). Both of these adipokines serve as excellent indicators of
whole body physiology. In each case, the levels of these hor-
mones are consistent with increased insulin resistance, adiposity,
and a propensity toward an obese phenotype. Unexpectedly,
we found reduced adipocyte differentiation potential in MEFs
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Fig. 4. SRC-3Δ/Δ mice display the hallmarks of
insulin resistance. (A) Measurement of blood
glucose and insulin levels in 9-mo-old SRC-3Δ/Δ
(ﬁlled bars; n = 5) compared with WT litter-
mate mice (open bars; n = 5) under fed or 24-h
fasting conditions. (B) Glucose tolerance test
and parallel insulin measurement of SRC-3Δ/Δ
(black line, n = 6) and WT littermate mice
(white line, n = 6). (C) Insulin tolerance test of
SRC-3Δ/Δ (black line, n = 6) and WT littermate
mice (white line, n = 6). Two-way ANOVA
analysis performed by using Area Under the
Curve (AUC) calculation of insulin tolerance
test results in SRC-3Δ/Δ (ﬁlled bars; n = 6) and
WT littermate mice (open bars; n = 6). (D)
Histological examination liver sections from
WT and SRC-3Δ/Δ littermate mice for H&E,
Periodic acid-Schiff staining (PAS), Oil Red O,
and H&E for WAT. (E) Quantitative enzymatic
analysis of liver glycogen levels in SRC-3Δ/Δ
(ﬁlled bars; n = 5) and WT littermate mice
(open bars; n = 5). (F and G) Plasma proﬁling
after 24 h fasting of triglycerides and adipo-
nectin in SRC-3Δ/Δ (ﬁlled bars; n = 5) and WT
littermate mice (open bars; n = 5). All data are
represented as the mean ± SEM. Unpaired
Student’s t test was used to evaluate statistical
signiﬁcance. *, P < 0.05; **, P < 0.01.
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isolated from SRC-3Δ/Δ mice compared with WT MEFs (Fig.
S6E). qPCR analysis of adipogenic PPARγ target genes over the
course of differentiation in SRC-3Δ/Δ and WTMEFs revealed no
signiﬁcant differences (Fig. S6F). Collectively, these data are
consistent with impaired peripheral insulin sensitivity, hypergly-
cemia, and increased adiposity.
SRC-3Δ/ΔMice Are Inherently More Susceptible to Carcinogen-Induced
Tumorigenesis. The observation that SRC-3Δ/Δ mice had elevated
circulating levels of IGF1 prompted us to investigate the potential
consequences of this phenotype on tumorigenesis. Evaluation of
total IGF1 levels in tissues of WT and SRC-3Δ/Δmice revealed no
increase in IGF1 in the liver (Fig. S7), suggesting that the ele-
vated circulating IGF1 was primarily due to increased production
of IGFBP3. To investigate the effect of elevated IGF1 in the
liver, WT and SRC-3Δ/Δmice were injected with the liver-speciﬁc
carcinogen, diethylnitrosamine (DEN). After 1 y, the livers of
SRC-3Δ/Δ mice appeared to be more susceptible to carcinogen-
induced tumorigenesis than WT mice (Fig. 5A). Closer exami-
nation revealed no change in liver weight when normalized to
body weight (Fig. 5B). SRC-3Δ/Δ mice displayed increases in the
numbers of visible tumors, average tumor size, and maximal tu-
mor size (Fig. 5 C–E). This increased tumor progression, coupled
with elevated IGF1 and hyperinsulinemia in the SRC-3Δ/Δ mice,
suggest that the canonical signal transduction pathways down-
stream of insulin and IGF1 may be elevated in these mice. West-
ern blot analyses of liver tumor extracts revealed a clear activation
of downstream components of the insulin/IGF1 signaling path-
ways in SRC-3Δ/Δ mice (Fig. 5F). Collectively, these data suggest
that SRC-3 regulation of IGFBP3 inﬂuences the activation of
IGF1 signaling pathways, which culminate to increase growth
capacity of hepatic tumors.
Discussion
From a mechanistic perspective, SRC-3 has served as a model
coactivator for how the PTM code of a “master growth co-
regulator” inﬂuences its cellular function. Our laboratory initially
identiﬁed the mechanism by which phosphorylation of SRC-3
directly controls its transcriptional coactivation potential (4). This
ﬁnding led us to discover that site-speciﬁc phosphorylation of
SRC-3 also can serve as a primer for subsequent ubiquintylation,
which can be a prerequisite for maximal transcriptional activity
and temporal turnover of SRC-3 (3). In addition to these studies,
we have demonstrated how phosphorylation of SRC-3 by differ-
ent kinases, and at different residues, confers distinct genetic
consequences. Although these data collectively point to the im-
portance of the PTM code in modulating the diverse functions of
SRC-3, understanding how this PTM code manifests changes at
the physiological level had not been evaluated. Thus, the de-
velopment of the SRC-3Δ/Δ mouse provided a unique and nec-
essary tool to test the in vivo signiﬁcance of changes in the PTM
code on SRC-3 systemic function.
The widespread metabolic changes observed in our PTM
knock-in model, coupled with impaired glucose homeostasis and
increased body weight, suggest that in vitro approaches are ef-
fective for evaluating speciﬁc gene functions (and pathways) of
phosphorylation sites, but often are incomplete in terms of pre-
dicting systemic physiological consequences. The metabolic alter-
ations observed in the present study suggest that the four speciﬁc
knock-in mutations converge on a global growth-signaling path-
way in a way that could not be predicted in advance. We reported
that deletion of the SRC-3 gene negatively impacts IGF1 signaling
in mice, likely resulting from impaired transcription of the
IGFBP3 gene (14). This deﬁciency reduces the pool of circulating
IGF1 and contributes to the decreased body weight observed
in the SRC-3−/− mice. Conversely, analysis of SRC-3Δ/Δ mice re-
vealed a marked increase in plasma IGF1 levels, which correlates
with (or likely results from) markedly elevated transcript and
protein levels of IGFBP3. One functional outcome of this ele-
vated IGF1 signaling is enhanced susceptibility to carcinogen-
induced tumor growth. Although, we are unable to deﬁnitively
discriminate between the direct oncogenic functions of mutant
SRC-3 and the role that these mutations play in bolstering IGF1
signaling, it is reasonable to assume that even indirectly, PTMs
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Fig. 5. SRC-3Δ/Δ mice are inherently more susceptible to carcinogen-induced tumorigenesis. (A) Representative macroscopic analysis of livers isolated from
SRC-3Δ/Δ andWT littermatemalemice treated for 12mowithDEN (Upper). H&E stainingof formalin-ﬁxed livers fromDEN-treated SRC-3Δ/Δ andWTmice (Lower).
(B)Measurement of liverweight as a percentage of bodyweight in DEN-treated SRC-3Δ/Δ (ﬁlled bars; n = 5) andWT littermatemice (open bars; n = 5). (C) Analysis
of total tumornumber fromDEN-treatedSRC-3Δ/Δ (ﬁlledbars;n=5) andWT littermatemice (openbars;n=5). (D)Measurementofaverage tumor sizedetermined
in C in DEN-treated SRC-3Δ/Δ (ﬁlled bars; n = 5) and WT littermate mice (open bars; n = 5). (E) Measurement of maximal tumor size determined from C in DEN-
treated SRC-3Δ/Δ (ﬁlled bars; n = 5) andWT littermatemice (open bars; n = 5). (F)Western blots of phosphorylated and total c-Raf,MEK1/2, p44/42, Akt, as well as
α-tubulin and β-actin from liver tumor tissue isolated fromWT (n = 4) and SRC-3Δ/Δ littermatemice (n = 4). All data are represented as themean± SEM. Unpaired
Student’s t test was used to evaluate statistical signiﬁcance. *, P < 0.05.
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on SRC-3 produce secondary effects on tumor growth, in addition
to its more direct oncogenic potential when overexpressed.
Several groups have reported on transgenic mouse models over-
expressing IGFBP3 (21, 22), which phenotypically share a number of
similarities to the SRC-3Δ/Δ mice. In particular, overexpression
of IGFBP3 results in elevated circulating levels of IGF1, insulin
resistance, and hyperglycemia, all of which were observed in our
SRC-3Δ/Δ mouse model. Additionally, both SRC-3Δ/Δ and IGFBP3
transgenic mice show a marked increase in epididymal fat pad mass.
Surprisingly, in the SRC-3Δ/Δ mice, this increase is not due to en-
hanced adipocyte differentiation, but rather when coupled with ele-
vated levels of triglycerides in the liver and the circulation, likely
points to increased lipogenesis. Again, these observations are con-
sistent with increased IGF1 signaling.
The obese phenotype observed in our SRC-3Δ/Δ mice was ac-
companied by the development of age-dependent insulin resis-
tance and hyperglycemia. Accordingly, the phenotype of our mouse
model resembles the metabolic syndrome seen in humans. This ob-
servation raises the interesting question whether PTMmodiﬁcations
of SRC-3 (or other coactivators) could play a role in the development
of obesity and type 2 diabetes. Because an increased prevalence of
some types of cancer occurs in concert with obesity, another in-
teresting question is whether SRC-3 could serve as a link between
these two conditions. Collectively, our work provides evidence that
functional combinations of endogenous PTMs can reprogram a sin-
gle coactivator like SRC-3 for speciﬁc functions that completely
alter the systems biology of an organism. Especially compared with
the growth and metabolic phenotypes of the SRC-3−/− mice, our
SRC-3Δ/Δ mice emphasize the general importance of PTMs as they
relate to in vivo coregulator function. Perhaps such studies of cor-
egulator PTMs will provide new therapeutic insights for intervention
in diseases such as type 2 diabetes, obesity, and cancer.
Experimental Procedures
Generation of SRC-3Δ/ΔMice. Complete details for generation of SRC-3Δ/Δmice
is described in the SI Experimental Procedures.
qPCR Assays. TotalmRNAwas isolated from liver, muscle, brain,WAT, or kidney
by using the RNeasy Kit (Qiagen). Reverse transcriptionwas carried out by using
the SuperScript II kit (Invitrogen) per the manufacturer’s instructions. For gene
expression analysis, qPCR was performed by using sequence-speciﬁc primers
and the Universal Probe Library (Roche). For all analyses, 18S was used as an
internal control. Sequences of all qPCR primers are available upon request.
Cell Culture, Transient Transfection, and Luciferase Assays. Primary WT and
SRC-3Δ/Δ MEFs were maintained in DMEM with 10% FBS. For transient-
transfection assays, MEFs were plated in six-well plates overnight and trans-
fected with pGL3-basic or pGL3-IGFBP3 (1-3590) plasmid containing the lu-
ciferase reporter by using the FuGENE 6 HD transfection reagent (Roche). All
cells were cotransfected with the pRSV-β-gal expression plasmid as a control
for transfection efﬁciency. Cell lysates were prepared 48 h after transfec-
tion, and the β-gal and luciferase activities were measured with a luciferase
assay kit (Promega). The relative luciferase units were normalized to the
β-gal activity.
Chromatin Immunoprecipitation. In vivo kidney ChIP was performed as de-
scribed (http://genomics.ucdavis.edu/farnham/protocols/tissues.html). Brieﬂy,
≈100 mg of whole kidney tissue isolated from SRC-3Δ/Δ, SRC-3+/+, or SRC-3−/−
mice was ﬁnely minced, cross-linked with 1% methanol-free formaldehyde
for 15 min, quenched in 125 mM glycine, and centrifuged at 2,000 × g at 4 °C.
The resulting pellets wereDounce homogenized in PBS containingMg2+/Ca2+,
protease inhibitors, and phosphatase inhibitors, then centrifuged again.
Pellets were resuspended in 300 μL of sonication buffer, and 100 μL of soni-
cated chromatin was immunoprecipitated with 4 μg of SRC-3 antibody (sc-
7216) or normal IgG (sc-2028) per our standard protocol. All primer sequences
are available upon request.
Tumor Induction and Analysis. Fifteen-day-old pups (SRC-3Δ/Δ and WT litter-
mates) were IP injected with 10 mg/kg diethylnitrosamine (Sigma). After 12
mo on normal chow, mice were weighed, killed, and their livers were re-
moved, analyzed, and photographed macroscopically. Livers were further
evaluated to determine the total tumor number, average tumor size, maxi-
mal tumor size, and liver weight. Samples of each liver tissue were prepared
for histology as described (23).
Statistical Analyses. All results are shown as the mean ± SEM. The comparison
of different groups was carried out by using two-tailed unpaired Student’s
t test, and differences at or below P < 0.05 were considered statistically
signiﬁcant.
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